TACSTD2 and cervical carcinoma: According to the previously published and present data, Trop2-directed ADC may represent a therapeutic option in cervical cancer patients regardless of histopathological subtype and p16 expression status acting as an immunohistochemical surrogate marker for HPV high-risk association.